Overview

Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment

Status:
Completed
Trial end date:
2006-10-12
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate how subjects with mild or moderate liver problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Casopitant